Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Esperion Announces Positive Topline Results from Phase 2 Diabetes Clinical Trial

Published: Thursday, January 10, 2013
Last Updated: Thursday, January 10, 2013
Bookmark and Share
Data show LDL-C lowering of up to 43% and beneficial effects on other relevant cardiometabolic risk factors to be presented at a future scientific meeting.

Esperion Therapeutics announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo. ETC-1002 therapy was also associated with improvements in control of additional cardiometabolic risk factors in this high-risk, difficult-to-treat patient population. The full data from this Phase 2 clinical trial will be presented at a future scientific meeting.

ETC-1002 is an investigational, once-daily, oral small molecule therapy that has been shown to be liver selective for activation of AMP kinase and inhibition of ATP citrate lyase. This dual mechanism of action has the potential to regulate imbalances in both hepatic lipid and carbohydrate metabolism. In the Phase 2 trial, 60 patients with type 2 diabetes received ETC-1002 or placebo for four weeks in an inpatient facility. In clinical research to date, ETC-1002 has shown an attractive safety profile, significant and consistent LDL-C lowering and beneficial effects on hsCRP, glucose and other cardiometabolic risk factors. ETC-1002 is currently being studied in multiple Phase 2 clinical trials.

“With these results, ETC-1002 has now been shown to be safe and well-tolerated in two Phase 2 studies. We continue to rapidly advance ETC-1002 through Phase 2 clinical development and we are exploring its efficacy in additional patient populations, with a particular focus on the growing statin-intolerant patient population. We look forward to presenting our clinical results in peer-reviewed settings later this year,” said Tim Mayleben, president and CEO of Esperion.

“People living with type 2 diabetes are at high risk for cardiovascular disease. For many, treatment with statins and other cardiometabolic therapies can impair glycemic control, potentially putting them at increased risk. With a novel mechanism of action designed to lower LDL-C and provide beneficial effects on glucose control, ETC-1002 has the potential to offer significant advantages for patients living with type 2 diabetes and for patients who are statin intolerant and/or not at the appropriate National Cholesterol Education Program (NCEP) LDL-C goal,” said Dr. Roger Newton, executive chairman and chief scientific officer of Esperion.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!